Go Pro
→ Here’s the stock symbol I’ve promised (From Stansberry Research) (Ad)tc pixel Free BFRIW Stock Alerts

Biofrontera (BFRIW) Competitors

Biofrontera logo
$0.02 +0.00 (+1.48%)
As of 09/16/2026 11:13 AM Eastern
Compare

BFRIW vs. SXTPW, CINGW, CLVR, CMRAW, and CDTTW

Should you buy Biofrontera stock or one of its competitors? Biofrontera's main competitors and comparable companies include 60 Degrees Pharmaceuticals (SXTPW), Cingulate (CINGW), Clever Leaves (CLVR), Comera Life Sciences (CMRAW), and Conduit Pharmaceuticals (CDTTW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Biofrontera compare to 60 Degrees Pharmaceuticals?

60 Degrees Pharmaceuticals (NASDAQ:SXTPW) and Biofrontera (NASDAQ:BFRIW) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership and risk.

In the previous week, 60 Degrees Pharmaceuticals and 60 Degrees Pharmaceuticals both had 3 articles in the media. 60 Degrees Pharmaceuticals' average media sentiment score of 0.30 equaled Biofrontera'saverage media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
60 Degrees Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Biofrontera
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
60 Degrees Pharmaceuticals$1.11MN/AN/AN/AN/A
Biofrontera$46.18MN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
60 Degrees PharmaceuticalsN/A N/A N/A
Biofrontera N/A N/A N/A

Summary

Biofrontera beats 60 Degrees Pharmaceuticals on 1 of the 1 factors compared between the two stocks.

How does Biofrontera compare to Cingulate?

Biofrontera (NASDAQ:BFRIW) and Cingulate (NASDAQ:CINGW) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, earnings, profitability, risk and dividends.

In the previous week, Biofrontera had 1 more articles in the media than Cingulate. MarketBeat recorded 3 mentions for Biofrontera and 2 mentions for Cingulate. Cingulate's average media sentiment score of 1.43 beat Biofrontera's score of 0.30 indicating that Cingulate is being referred to more favorably in the news media.

Company Overall Sentiment
Biofrontera Neutral
Cingulate Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biofrontera$46.18MN/AN/AN/AN/A
CingulateN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
BiofronteraN/A N/A N/A
Cingulate N/A N/A N/A

Summary

Biofrontera beats Cingulate on 2 of the 3 factors compared between the two stocks.

How does Biofrontera compare to Clever Leaves?

Clever Leaves (NASDAQ:CLVR) and Biofrontera (NASDAQ:BFRIW) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability.

6.9% of Clever Leaves shares are held by institutional investors. 8.2% of Clever Leaves shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Company Net Margins Return on Equity Return on Assets
Clever LeavesN/A N/A N/A
Biofrontera N/A N/A N/A

In the previous week, Biofrontera had 3 more articles in the media than Clever Leaves. MarketBeat recorded 3 mentions for Biofrontera and 0 mentions for Clever Leaves. Biofrontera's average media sentiment score of 0.30 beat Clever Leaves' score of 0.00 indicating that Biofrontera is being referred to more favorably in the news media.

Company Overall Sentiment
Clever Leaves Neutral
Biofrontera Neutral

Biofrontera has higher revenue and earnings than Clever Leaves.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Clever Leaves$17.42M0.00-$17.90M-$9.66N/A
Biofrontera$46.18MN/AN/AN/AN/A

Summary

Biofrontera beats Clever Leaves on 3 of the 5 factors compared between the two stocks.

How does Biofrontera compare to Comera Life Sciences?

Biofrontera (NASDAQ:BFRIW) and Comera Life Sciences (NASDAQ:CMRAW) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, dividends, profitability, risk and valuation.

Company Net Margins Return on Equity Return on Assets
BiofronteraN/A N/A N/A
Comera Life Sciences N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biofrontera$46.18MN/AN/AN/AN/A
Comera Life Sciences$1.00MN/AN/AN/AN/A

In the previous week, Biofrontera had 3 more articles in the media than Comera Life Sciences. MarketBeat recorded 3 mentions for Biofrontera and 0 mentions for Comera Life Sciences. Biofrontera's average media sentiment score of 0.30 beat Comera Life Sciences' score of 0.00 indicating that Biofrontera is being referred to more favorably in the media.

Company Overall Sentiment
Biofrontera Neutral
Comera Life Sciences Neutral

Summary

Biofrontera beats Comera Life Sciences on 3 of the 3 factors compared between the two stocks.

How does Biofrontera compare to Conduit Pharmaceuticals?

Biofrontera (NASDAQ:BFRIW) and Conduit Pharmaceuticals (NASDAQ:CDTTW) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, analyst recommendations, dividends, valuation and profitability.

In the previous week, Biofrontera had 2 more articles in the media than Conduit Pharmaceuticals. MarketBeat recorded 3 mentions for Biofrontera and 1 mentions for Conduit Pharmaceuticals. Conduit Pharmaceuticals' average media sentiment score of 1.89 beat Biofrontera's score of 0.30 indicating that Conduit Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Biofrontera Neutral
Conduit Pharmaceuticals Very Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biofrontera$46.18MN/AN/AN/AN/A
Conduit PharmaceuticalsN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
BiofronteraN/A N/A N/A
Conduit Pharmaceuticals N/A N/A N/A

Summary

Biofrontera beats Conduit Pharmaceuticals on 2 of the 3 factors compared between the two stocks.

Get Biofrontera News Delivered to You Automatically

Sign up to receive the latest news and ratings for BFRIW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BFRIW vs. The Competition

Export
MetricBiofronteraPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market CapN/A$12.54B$7.23B$14.93B
Dividend YieldN/A2.64%2.57%12.31%
P/E RatioN/A794.72273.8625.33
Price / SalesN/A753.87639.9687.33
Price / CashN/A85.4276.4050.90
Price / BookN/A10.4110.366.24
Net IncomeN/A$2.84B$3.49B$358.55M
7 Day PerformanceN/A-1.09%-0.81%-1.20%
1 Month PerformanceN/A0.88%-1.35%-4.26%
1 Year PerformanceN/A4.08%21.15%5.47%

Biofrontera Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BFRIW
Biofrontera
N/A$0.02
+1.5%		N/A-80.7%$0.00$46.18MN/A70
SXTPW
60 Degrees Pharmaceuticals
N/A$0.03
flat		N/A-20.9%$0.00$1.11MN/A2
CINGW
Cingulate
N/A$0.01
-18.6%		N/A-87.5%$0.00N/AN/A20
CLVR
Clever Leaves
N/A$0.00
flat		N/A-50.0%$0.00$17.42MN/A560
CMRAW
Comera Life Sciences
N/AN/AN/AN/A$0.00$1.00MN/A2

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:BFRIW) was last updated on 9/17/2026 by MarketBeat.com Staff.
From Our Partners
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
Bank of America: 'Digital Dollar Inevitable'
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel
Your withdrawal order could cost you in taxes
If you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...
SmartAsset | Sponsoredtc pixel